Original Article

You have full text access to this OnlineOpen article

Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis

  1. Milan Lukas MD, PhD1,*,
  2. Pavel Drastich MD, PhD2,
  3. Michal Konecny MD, PhD3,
  4. Paolo Gionchetti MD4,
  5. Ondrej Urban MD, PhD6,
  6. Franco Cantoni MD5,
  7. Martin Bortlik MD, PhD1,
  8. Dana Duricova MD1,
  9. Michael Bulitta Dipl.-Stat7

Article first published online: 2 NOV 2009

DOI: 10.1002/ibd.21161

Issue

Inflammatory Bowel Diseases

Inflammatory Bowel Diseases

Volume 16, Issue 7, pages 1180–1186, July 2010

Additional Information

How to Cite

Lukas, M., Drastich, P., Konecny, M., Gionchetti, P., Urban, O., Cantoni, F., Bortlik, M., Duricova, D. and Bulitta, M. (2010), Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis. Inflamm Bowel Dis, 16: 1180–1186. doi: 10.1002/ibd.21161

Author Information

  1. 1

    Centre for Gastroenterology, University Hospital, Prague, Czech Republic

  2. 2

    Institute of Clinical and Experimental Medicine, Prague, Czech Republic

  3. 3

    II Medical Department, University Hospital, Olomouc, Czech Republic

  4. 4

    Dept Internal Medicine and Gastroenterology, S Orsola Hospital, Bologna, Italy

  5. 5

    Department of Internal Medicine, Vitkovice Hospital, Ostrava-Vitkovice, Czech Republic

  6. 6

    Department of Gastroenterology, Ospedale S Maria delle Croci, Ravenna, Italy

  7. 7

    CRM Biometrics GmbH, Rheinbach, Germany

*IBD Clinical and Research Centre, ISCARE IVF as 1st Medical Faculty, Charles University, Jankovcova 1569/2c, 17 00 Prague 7, Czech Republic

Publication History

  1. Issue published online: 11 JUN 2010
  2. Article first published online: 2 NOV 2009
  3. Manuscript Accepted: 1 OCT 2009
  4. Manuscript Received: 29 SEP 2009

Funded by

  • Supported by AM-Pharma BV, Bunnik, The Netherlands, who provided AP enzyme for the study

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (109K)

REFERENCES

  • 1
    Harris H. The human alkaline phosphatases: what we know and what we don't know. Clin Chim Acta. 1990; 186: 133–150.
  • 2
    Alkaline phosphatases. McCombRB, BowersJrGN, PosenS, eds. New York: Plenum Press; 1979.
  • 3
    O'Brien PJ, Herschlag D. Functional interrelationships in the alkaline phosphatase superfamily: phosphodiesterase activity of Escherichia coli alkaline phosphatase. Biochemistry. 2001; 40: 5691–5699.
  • 4
    Yang C, Kong J, Wang Q, et al. Heterosis of haemolymph analytes of two geographic populations in Chinese shrimp Fenneropenaeus chinensis. Fish Shellfish Immunol. 2007; 23: 62–70.
  • 5
    Millán JL. Alkaline phosphatases: structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes. Purinergic Signal. 2006; 2: 335–341.
  • 6
    Anon. Monograph Summary: EC 3.1.3.1: Alkaline phosphatase, of Phosphoric Monoester Hydrolases (EC 3.1.3), of Acting on Ester Bonds (EC 3.1), of Hydrolases (EC 3); IntEnz Enzyme Nomenclature. http://www.ebi.ac.uk/intenz/query?cmd=SearchEC&ec=3.1.3.1
  • 7
    Stigbrand T, Millán JL, Fishman WH. The genetic basis of alkaline phosphatase isozyme expression. Isozymes Curr Top Biol Med Res. 1982; 6: 93–117.
  • 8
    Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001; 414: 916–920.
  • 9
    Picher M, Burch LH, Hirsh AJ, et al. Ecto 5′-nucleotidase and nonspecific alkaline phosphatase. Two AMP-hydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem. 2003; 278: 13468–13479.
  • 10
    Vaishnava S, Hooper LV. Alkaline phosphatase: keeping the peace at the gut epithelial surface. Cell Host Microbe. 2007; 2: 365–367.
  • 11
    Malo MS, Biswas S, Abedrapo MA, et al. The pro-inflammatory cytokines, IL-1beta and TNF-alpha, inhibit intestinal alkaline phosphatase gene expression. DNA Cell Biol. 2006; 25: 684–695.
  • 12
    Poelstra K, Bakker WW, Klok PA, et al. Dephosphorylation of endotoxin by alkaline phosphatase in vivo. Am J Pathol. 1997; 151: 1163–1169.
  • 13
    Poelstra K, Bakker WW, Klok PA, et al. A physiologic function for alkaline phosphatase: endotoxin detoxification. Lab Invest. 1997; 76: 319–327.
  • 14
    Bentala H, Verweij WR, Huizinga-Van der Vlag A, et al. Removal of phosphate from lipid a as a strategy to detoxify lipopolysaccharide. Shock 2002; 18: 561–566.
  • 15
    Beumer C, Wulferink M, Raaben W, et al. Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets. J Pharmacol Exp Ther. 2003; 307: 737–744.
  • 16
    Bates JM, Akerlund J, Mittge E, et al. Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. Cell Host Microbe. 2007; 2: 371–382.
  • 17
    Domar U, Nilsson B, Baranov V, et al. Expression of intestinal alkaline phosphatase in human organs. Histochemistry. 1992; 98: 359–364.
  • 18
    Tuin A, Poelstra K, Jager-Krikken A, et al. Role of alkaline phosphatase in colitis in man and rats. Gut. 2009; 58: 379–382.
  • 19
    Pickkers P, Snellen F, Rogiers P, et al. Clinical pharmacology of exogenously administered alkaline phosphatase. Eur J Clin Pharmacol. 2009; 65: 393–402.
  • 20
    Heemskerk S, Masereeuw R, Moesker O, et al. Alkaline Phosphatase treatment improves renal function in patients with severe sepsis or septic shock. Crit Care. 2007; 11( suppl 2):P 14. Abstract.
  • 21
    Tung CB, Tung CF, Yang DY, et al. Extremely high levels of alkaline phosphatase in adult patients as a manifestation of bacteremia. Hepatogastroenterology. 2005; 52: 1347–1350.
  • 22
    Maldonado O, Demasi R, Maldonado Y, et al. Extremely high levels of alkaline phosphatase in hospitalized patients. J Clin Gastroenterol. 1998; 27: 342–345.
  • 23
    Rojo OP, Roman ALS, Arbizu EA, et al. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13: 269–277.
    Direct Link:
  • 24
    Amati L, Caradonna L, Leandro G, et al. Immune abnormalities and endotoxemia in patients with ulcerative colitis and in their first degree relatives: attempts at neutralizing endotoxin-mediated effects. Curr Pharm Des. 2003; 9: 1937–1945.
  • 25
    Caradonna L, Amati L, Magrone T, et al. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J Endotoxin Res. 2000; 6: 205–214.
  • 26
    Ramasamy S, Malo MS, Mostafa G, et al. A potential role for intestinal alkaline phosphatase in colonic inflammation. Gastroenterology. 2009; 136( suppl 1): Poster Presentation, Abstract S1670. http://download.abstractcentral.com/DDW2009/myddw2009/S1670.html
  • 27
    Chen K, Malo MS, Zeller S. Intestinal alkaline phosphatase protects against mucosal inury by commensal bacteria: elucidation of mechanism. Gastroenterology. 2009; 136( suppl 1): Poster Presentation, Abstract T1856.http://download.abstractcentral.com/DDW2009/myddw2009/T1856. html
  • 28
    Anon. International Conference on Harmonization; Harmonized Tripartite Guideline; General Considerations for Clinical Trials; Section 2.0: General Principles; Subsection 2.2: Scientific Approach to Design and Analysis. http://www.ich.org/LOB/media/MEDIA484.pdf
  • 29
    Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19( suppl A): 5–36.
  • 30
    European Medicines Agency. EMEA/CPMP/CVMP: note for guidance on minimizing the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMEA/410/01rev.2). http://www.emea.europa.eu/pdfs/human/bwp/TSE%20NGF% 20410-rev2.pdf
  • 31
    Wulferink M, Brands R, Raaben W, et al. Pharmacokinetics and safety of BIAP administered as a single bolus in the duodenum, jejunum and ileum in piglets. AM-Pharma (internal) Preclinical Report: ( 2005) Study AP-IBD-PC003/004.
  • 32
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462–2476.
  • 33
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ. 1955; 2: 1041–1048.
  • 34
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med. 1987; 317: 1625–1629.
  • 35
    D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132: 763–786.
  • 36
    Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007; 133: 1099–1105.
  • 37
    Anon. World Health Organization, International Conference on Harmonization Topic E6 Guideline for Good Clinical Practice. US Federal Register, Vol. 62, No. 90, May 9, 1997: 2561–2570E7. http://www.ich.org/LOB/media/MEDIA482.pdf
  • 38
    Bours MJL, Swennen ERL, Di Virgilio F, et al. Adenosine 5′-triphosphate and adenosine as endogenous signalling molecules in immunity and inflammation. Pharmacol Ther. 2006; 112: 358–404.
View Full Article (HTML) Get PDF (109K)